Literature DB >> 30429343

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Benedikt Asbach1, Karen V Kibler2, Josef Köstler3, Beatriz Perdiguero4, Nicole L Yates5, Sherry Stanfield-Oakley5, Georgia D Tomaras5, Shing-Fen Kao6, Kathryn E Foulds6, Mario Roederer6, Michael S Seaman7, David C Montefiori5, Robert Parks5, Guido Ferrari5, Donald N Forthal8, Sanjay Phogat9, James Tartaglia9, Susan W Barnett10, Steven G Self11, Raphael Gottardo11, Anthony D Cristillo12, Deborah E Weiss12, Lindsey Galmin12, Song Ding13, Jonathan L Heeney14, Mariano Esteban4, Bertram L Jacobs2, Giuseppe Pantaleo15, Ralf Wagner16,3.   

Abstract

The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different delivery modalities, three different poxvirus boost regimens were compared. Three groups of rhesus macaques were each primed with the same DNA vaccine encoding Gag, Pol, Nef, and gp140. The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved replication competence in human cells, termed NYVAC-KC. The latter was administered either by scarification or intramuscularly. Finally, macaques were boosted with adjuvanted gp120 protein to enhance humoral responses. The regimen elicited very potent CD4+ and CD8+ T cell responses in a well-balanced manner, peaking 2 weeks after the boost. T cells were broadly reactive and polyfunctional. All animals exhibited antigen-specific humoral responses already after the poxvirus boost, which further increased following protein administration. Polyclonal reactivity of IgG antibodies was highest against HIV-1 clade C Env proteins, with considerable cross-reactivity to other clades. Substantial effector functional activities (antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated virus inhibition) were observed in serum obtained after the last protein boost. Notably, major differences between the groups were absent, indicating that the potent priming induced by the DNA vaccine initially framed the immune responses in such a way that the subsequent boosts with NYVAC and protein led only to an increase in the response magnitudes without skewing the quality. This study highlights the importance of selecting the best combination of vector systems in heterologous prime-boost vaccination regimens.IMPORTANCE The evaluation of HIV vaccine efficacy trials indicates that protection would most likely correlate with a polyfunctional immune response involving several effector functions from all arms of the immune system. Heterologous prime-boost regimens have been shown to elicit vigorous T cell and antibody responses in nonhuman primates that, however, qualitatively and quantitatively differ depending on the respective vector systems used. The present study evaluated a DNA prime and poxvirus and protein boost regimen and compared how two poxvirus vectors with various degrees of replication capacity and two different delivery modalities-conventional intramuscular delivery and percutaneous delivery by scarification-impact several immune effectors. It was found that despite the different poxvirus boosts, the overall immune responses in the three groups were similar, suggesting the potent DNA priming as the major determining factor of immune responses. These findings emphasize the importance of selecting optimal priming agents in heterologous prime-boost vaccination settings.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  DNA vaccine; Gag-Pol-Nef; NYVAC; NYVAC-KC; T cell responses; antibody responses; gp140; human immunodeficiency virus; nonhuman primates; vaccine

Mesh:

Substances:

Year:  2019        PMID: 30429343      PMCID: PMC6340047          DOI: 10.1128/JVI.01529-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

Review 1.  The germinal center reaction.

Authors:  Dominique Gatto; Robert Brink
Journal:  J Allergy Clin Immunol       Date:  2010-11       Impact factor: 10.793

Review 2.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

3.  EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

Authors:  Sheena McCormack; Wolfgang Stöhr; Tristan Barber; Pierre-Alexandre Bart; Alexandre Harari; Christiane Moog; Donatella Ciuffreda; Cristina Cellerai; Miranda Cowen; Romilda Gamboni; Séverine Burnet; Ken Legg; Elizabeth Brodnicki; Hans Wolf; Ralf Wagner; Jonathan Heeney; Marie-Joëlle Frachette; Jim Tartaglia; Abdel Babiker; Giuseppe Pantaleo; Jonathan Weber
Journal:  Vaccine       Date:  2008-05-06       Impact factor: 3.641

4.  Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.

Authors:  Juan García-Arriaza; Beatriz Perdiguero; Jonathan Heeney; Michael Seaman; David C Montefiori; Celia Labranche; Nicole L Yates; Xiaoying Shen; Georgia D Tomaras; Guido Ferrari; Kathryn E Foulds; Adrian McDermott; Shing-Fen Kao; Mario Roederer; Natalie Hawkins; Steve Self; Jiansheng Yao; Patrick Farrell; Sanjay Phogat; Jim Tartaglia; Susan W Barnett; Brian Burke; Anthony Cristillo; Deborah Weiss; Carter Lee; Karen Kibler; Bert Jacobs; Benedikt Asbach; Ralf Wagner; Song Ding; Giuseppe Pantaleo; Mariano Esteban
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

5.  High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.

Authors:  Justin Pollara; Lydia Hart; Faraha Brewer; Joy Pickeral; Beverly Z Packard; James A Hoxie; Akira Komoriya; Christina Ochsenbauer; John C Kappes; Mario Roederer; Ying Huang; Kent J Weinhold; Georgia D Tomaras; Barton F Haynes; David C Montefiori; Guido Ferrari
Journal:  Cytometry A       Date:  2011-07-06       Impact factor: 4.355

6.  NYVAC: a highly attenuated strain of vaccinia virus.

Authors:  J Tartaglia; M E Perkus; J Taylor; E K Norton; J C Audonnet; W I Cox; S W Davis; J van der Hoeven; B Meignier; M Riviere
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

7.  Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies.

Authors:  Mitzi M Donaldson; Shing-Fen Kao; Leila Eslamizar; Connie Gee; Gerrit Koopman; Michelle Lifton; Joern E Schmitz; Andrew W Sylwester; Aaron Wilson; Natalie Hawkins; Steve G Self; Mario Roederer; Kathryn E Foulds
Journal:  J Immunol Methods       Date:  2012-08-28       Impact factor: 2.303

8.  Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Authors:  Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

9.  Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.

Authors:  Clement A Meseda; Vajini Atukorale; Jordan Kuhn; Falko Schmeisser; Jerry P Weir
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

10.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Authors:  Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Heeney; Marie-Joelle Frachette; James Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  11 in total

1.  Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Authors:  Karen V Kibler; Benedikt Asbach; Beatriz Perdiguero; Juan García-Arriaza; Nicole L Yates; Robert Parks; Sherry Stanfield-Oakley; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Mario Roederer; Kathryn E Foulds; Donald N Forthal; Michael S Seaman; Steve Self; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan Barnett; Anthony D Cristillo; Deborah Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Ralf Wagner; Giuseppe Pantaleo; Bertram L Jacobs
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  A Novel Cre Recombinase-Mediated In Vivo Minicircle DNA (CRIM) Vaccine Provides Partial Protection against Newcastle Disease Virus.

Authors:  Yanlong Jiang; Xing Gao; Ke Xu; Jianzhong Wang; Haibin Huang; Chunwei Shi; Wentao Yang; Yuanhuan Kang; Roy Curtiss; Guilian Yang; Chunfeng Wang
Journal:  Appl Environ Microbiol       Date:  2019-07-01       Impact factor: 4.792

3.  Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.

Authors:  Yves Lévy; Christine Lacabaratz; Kim Ellefsen-Lavoie; Wolfgang Stöhr; Jean-Daniel Lelièvre; Pierre-Alexandre Bart; Odile Launay; Jonathan Weber; Bernd Salzberger; Aurélie Wiedemann; Mathieu Surenaud; David M Koelle; Hans Wolf; Ralf Wagner; Véronique Rieux; David C Montefiori; Nicole L Yates; Georgia D Tomaras; Raphael Gottardo; Bryan Mayer; Song Ding; Rodolphe Thiébaut; Sheena McCormack; Geneviève Chêne; Giuseppe Pantaleo
Journal:  PLoS Pathog       Date:  2020-06-26       Impact factor: 6.823

4.  A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.

Authors:  Beatriz Perdiguero; Cristina Sánchez-Corzo; Carlos Oscar S Sorzano; Lidia Saiz; Pilar Mediavilla; Mariano Esteban; Carmen Elena Gómez
Journal:  Viruses       Date:  2019-02-16       Impact factor: 5.048

5.  Der p2‑A20 DNA vaccine attenuates allergic inflammation in mice with allergic rhinitis.

Authors:  Wenhui Hu; Li Ma; Gui Yang; Xianhai Zeng; Jiangqi Liu; Baohui Cheng; Tianyong Hu; Hailiang Zhao; Zhiqiang Liu
Journal:  Mol Med Rep       Date:  2019-10-21       Impact factor: 2.952

6.  Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.

Authors:  Beatriz Perdiguero; Carmen Elena Gómez; Juan García-Arriaza; Cristina Sánchez-Corzo; Carlos Óscar S Sorzano; Sarah Wilmschen; Dorothee von Laer; Benedikt Asbach; Christina Schmalzl; David Peterhoff; Song Ding; Ralf Wagner; Janine Kimpel; Yves Levy; Giuseppe Pantaleo; Mariano Esteban
Journal:  Front Immunol       Date:  2019-12-18       Impact factor: 7.561

7.  COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.

Authors:  Juan García-Arriaza; Urtzi Garaigorta; Patricia Pérez; Adrián Lázaro-Frías; Carmen Zamora; Pablo Gastaminza; Carlos Del Fresno; José M Casasnovas; Carlos Óscar S Sorzano; David Sancho; Mariano Esteban
Journal:  J Virol       Date:  2021-01-07       Impact factor: 5.103

8.  Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge.

Authors:  Delphine C Malherbe; Lo Vang; Jason Mendy; Philip T Barnette; David A Spencer; Jason Reed; Bettie W Kareko; D Noah Sather; Shilpi Pandey; Constantinos K Wibmer; Harlan Robins; Deborah H Fuller; Byung Park; Samir K Lakhashe; James M Wilson; Michael K Axthelm; Ruth M Ruprecht; Penny L Moore; Jonah B Sacha; Ann J Hessell; Jeff Alexander; Nancy L Haigwood
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

9.  Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs.

Authors:  Patrick Neckermann; Ditte Rahbaek Boilesen; Torsten Willert; Cordula Pertl; Silke Schrödel; Christian Thirion; Benedikt Asbach; Peter Johannes Holst; Ralf Wagner
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

10.  Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design.

Authors:  Yik Chun Wong; Sarah Croft; Stewart A Smith; Leon C W Lin; Tania Cukalac; Nicole L La Gruta; Ingo Drexler; David C Tscharke
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.